Immune response targeting molecules

Details Immune response targeting molecules Immune response targeting molecules

2002-06-28

2008-09-09

Ouspenski, Ilia (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07423016

ABSTRACT:
The present invention provides methods of enhancing the immune response to an immunogen and to compositions for use in these methods. In particular the present invention provides a DNA molecule for use in raising an immune response to an antigen. The DNA molecule includes a first sequence encoding a targeting molecule, a second sequence encoding the antigen or an epitope thereof, and optionally a third sequence encoding a polypeptide which promotes dimerization or multimerization of the product encoded by the DNA molecule.

REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5698679 (1997-12-01), Nemazee
patent: 5851795 (1998-12-01), Linsley et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6224870 (2001-05-01), Segal
patent: WO 96/40941 (1996-12-01), None
Baier et al., “Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody fab fragments in vitro,”J. Virol., 69(4):2357-2365, 1995.
Boyle et al., “Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction,”Nature, 392:408-411, 1998.
Brumeanu et al., “Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes,”Immunotechnology, 2:85-95, 1996.
Corthesy et al., “A pathogen-specific epitope inserted into recombinant secretory immunoglobulin A is immunogenic by the oral route,”J. Biol. Chem., 271(52):33670-33677, 1996.
Huang et al., “Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen,”Blood, 96:3663-3669, 2000.
Lebens and Holmgren, “Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier,”Dev. Biol. Stand., 82:215-217, 1994.
Liu et al., “FcγR1-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonistic T cell epitopes,”J. Clin. Invest., 98:2001-2007, 1996.
Skea et al., “Studies of the adjuvant-independent antibody response to immunotargeting. Target structure dependence, isotype distribution, and induction of long term memory,”J. Immunol., 151:3557-3568, 1993.
Blast search results, www.ncbi.nlm.nih.gov/BLAST/Blast.cgi, (Feb. 20, 2007), pp. 1-6.
“CTLA-4-Ig” Mar. 25, 2006; hublog.hubmed.org/archives/001341.html, downloaded Oct. 15, 2007.
Orencia®, Mar. 2007, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA.
Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m (RG2077), clinicaltrials.gov/ct/show/NCT0094380?order=1, downloaded Oct. 4, 2007.
So et al., Immunitherapeutic Effects of CTLA4Ig Fusion Protein on Murine EAE and GVHD,Immune Netw., Dec. 2003, vol. 3, No. 4, pp. 302-309, Abstract only, koreamed.org/DisplaySearchResultText.php, downloaded Oct. 4, 2007.
Shiraishi et al., “Prevention of Acute Lung Allograft Rejection in Rat by CTLA4Ig,”American Journal of Transplantation, 2002, vol. 2, pp. 223-228, Blackwell Munksgaard, 2002.

Affiliated with

Also associated with

Rating

Immune response targeting molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immune response targeting molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune response targeting molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3967259